CLAIMS

1. Use of a pharmaceutically effective amount of at least one TPP-derivative compound and a pharmaceutically acceptable carrier in the manufacture of a medicament for treating at least one of tumor recurrence and metastasis, drug resistance, and radiotherapy resistant, the at least one TPP-derivative compound comprising at least one of: 2-butene-1,4-bis-TPP; 2-chlorobenzyl-TPP; 3-methylbenzyl-TPP; 2,4-dichlorobenzyl-TPP; 1-naphthylmethyl-TPP; and p-xylylenebis-TPP.

2. The use of claim 1, wherein the TPP-derivative compound comprises 2-butene-1,4-bis-TPP.

3. The use of claim 1, further comprising at least one therapeutic agent having an anti-mitochondrial effect.

4. The use of claim 3, wherein the at least one therapeutic agent having an anti-mitochondrial effect comprises at least one of an antibiotic, a chemotherapeutic, a nutraceutical, a mitochondrial biogenesis inhibitor, a mitoriboscin, a mitoketoscin, a mitoribocycline, a mitoribomycin, a mitoribosporin, a mitoribofloxin, an oxidative metabolism inhibitor, and a glycolytic metabolism inhibitor.

5. Use of a pharmaceutically effective amount of at least one TPP-derivative compound and a pharmaceutically acceptable carrier in the manufacture of a medicament for preventing at least one of tumor recurrence and metastasis, drug resistance, and radiotherapy resistance, the at least one TPP-derivative compound comprising at least one of: 2-butene-1,4-bis-TPP; 2-chlorobenzyl-TPP; 3-methylbenzyl-TPP; 2,4-dichlorobenzyl-TPP; 1-naphthylmethyl-TPP; and p-xylylenebis-TPP.

6. The use of claim 5, further comprising at least one therapeutic agent having an anti-mitochondrial effect.

7. The use of claim 6, wherein the at least one therapeutic agent having an anti-mitochondrial effect comprises at least one of an antibiotic, a chemotherapeutic, a nutraceutical, a mitochondrial biogenesis inhibitor, a mitoriboscin, a mitoketoscin, a mitoribocycline, a mitoribomycin, a mitoribosporin, a mitoribofloxin, an oxidative metabolism inhibitor, and a glycolytic metabolism inhibitor.

8. Use of a pharmaceutically effective amount of at least one TPP-derivative compound and a pharmaceutically acceptable carrier in the manufacture of a medicament for treating cancer,

the at least one TPP-derivative compound comprising at least one of: 2-butene-1,4-bis-TPP; 2-chlorobenzyl-TPP; 3-methylbenzyl-TPP; 2,4-dichlorobenzyl-TPP; and 1-naphthylmethyl-TPP.

9. The use of claim 8, further comprising at least one therapeutic agent having an anti-mitochondrial effect.

10. The use of claim 8, wherein the at least one TPP-derivative compound comprises 2-butene-1,4-bis-TPP.

11. The use of claim 8, wherein the at least one TPP-derivative compound selectively targets at least one of bulk cancer cells, CSCs, and energetic cancer stem cells.

12. The use of claim 11, wherein the at least one TPP-derivative compound selectively targets normal senescent cells.

13. The use of claim 8, wherein the at least one TPP-derivative compound is non-toxic to normal healthy cells.

14. The use of claim 9, wherein the at least one therapeutic agent having an anti-mitochondrial effect comprises at least one of an antibiotic, a mitochondrial biogenesis inhibitor, a mitoriboscin, a mitoketoscin, a mitoribocycline, a mitoribomycin, a mitoribosporin, a mitoribofloxin, an oxidative metabolism inhibitor, and a glycolytic metabolism inhibitor.

15. The use of claim 14, wherein the glycolytic metabolism inhibitor comprises at least one of a glycolysis inhibitor, an OXPHOS inhibitor, and an autophagy inhibitor.

16. An anti-cancer pharmaceutical composition comprising: at least one TPP-derivative compound comprising at least one of: 2-butene-1,4-bis-TPP; 2-chlorobenzyl-TPP; 3-methylbenzyl-TPP; 2,4-dichlorobenzyl-TPP; 1-naphthylmethyl-TPP; and p-xylylenebis-TPP; and at least one therapeutic agent having an anti-mitochondrial effect.

17. The composition of claim 16, wherein the at least one TPP-derivative compound is 2-butene-1,4-bis-TPP.

18. The composition of claim 16, wherein the at least one TPP-derivative compound eradicates at least one of bulk cancer cells, cancer stem cells, energetic cancer stem cells, and normal senescent cells.

19. The composition of claim 16, wherein the TPP-derivative compound is non-toxic towards normal healthy cells.

20. The composition of claim 16, wherein the composition possesses at least one of radiosensitizing activity, photosensitizing activity, and activity to sensitive cancer cells to at least one of chemotherapeutic agents, natural substances, and caloric restriction.

21. A pharmaceutical composition comprising 2-butene-1,4-bis-TPP and at least one therapeutic agent having an anti-mitochondrial effect.

22. The pharmaceutical composition of claim 21 wherein the at least one therapeutic agent comprises at least one of an antibiotic, a mitochondrial biogenesis inhibitor, a mitoriboscin, a mitoketoscin, a mitoribocycline, a mitoribomycin, a mitoribosporin, a mitoribofloxin, an oxidative metabolism inhibitor, and a glycolytic metabolism inhibitor.